Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

People with the thalassemia trait, or thalassemia carriers, may not experience any symptoms. However, some thalassemia carriers can experience anemia symptoms, such as paleness and fatigue. In people ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

Agios Pharmaceuticals said a key European regulatory committee has recommended expanded approval of its Pyrukynd anemia drug for certain people with the inherited blood disorder thalassemia. Agios on ...

Iron deficiency anemia (IDA) and thalassemia represent two of the most prevalent causes of microcytic anemia worldwide. Effective screening is critical not only to guide appropriate treatment — as IDA ...

Investigators used MRI to evaluate brain perfusion in patients with transfusion-dependent (n=54) and non–transfusion-dependent (n=23) β-thalassemia versus 56 controls. They found that relative ...

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

The thalassemia market is primarily driven by regular blood transfusions and iron chelation therapies, which help manage anemia and prevent iron overload. Curative treatments, such as stem cell ...

Sickle cell thalassemia occurs when you inherit both a sickle cell gene mutation and a thalassemia gene mutation. Symptoms are similar to other types of sickle cell disease but can vary depending on ...

AAPI Nexus: Asian Americans and Pacific Islanders, Policy, Practice and Community, Vol. 4, No. 2, Youth (Summer/Fall 2006), pp. 111-134 (24 pages) Thalassemia is a potentially life-threatening genetic ...

Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in ...

India accounts for approximately 25 per cent of the world’s β-thalassemia cases, with an estimated 42 million carriers nationwide. Every year, between 10,000 and 15,000 children are born with ...